Amplatzer™ Muscular VSD Occluders

amplatzer occluder banner

Closure of Ventricular Septal Defects (VSD)

Ventricular septal defects are the most commonly found congenital heart defect.1 One subtype of these defects is the muscular VSD. If left untreated, it can lead to pulmonary hypertension and/or congestive heart failure.2 The Amplatzer™ Muscular VSD Occluders are designed for complete closure of these type of defects.

Quality Engineering

Device Features

  • Device waist centers and closes the defect
  • Symmetrical design allows a transcatheter femoral or arterial delivery approach
  • Constructed from self-expanding Nitinol mesh and polyester material, which promotes tissue in-growth
  • Precise placement through the device’s ability to be recaptured and redeployed
     

Amplatzer™ Muscular VSD Occluder

The Amplatzer™ Muscular VSD Occluder is intended for the closure of congenital ventricular septal defects in high-risk surgical patients. The 7 mm waist length is designed to accommodate the thickness of the muscular ventricular septal wall.

Amplatzer Muscular VSD Occluders

Amplatzer™ P.I. Muscular VSD Occluder

The Amplatzer™ P.I. Muscular VSD Occluder is intended for the closure of post myocardial infarction (P.I.) VSD. The 10 mm waist length is designed to accommodate the damaged muscular tissue of the septal wall following a myocardial infarction.

Amplatzer Muscular VSD Occluders

 

Designed for Optimal Occlusion

The Amplatzer Muscular VSD Occluder and Amplatzer P.I. Muscular VSD Occluder are self-expandable, double-disc devices made from a nitinol wire mesh and polyester material. The two discs are linked together by a connecting waist corresponding to the size of the VSD, providing optimal occlusion.

 

Get the Amplatzer Portfolio App

The Amplatzer Portfolio App helps physicians determine which Amplatzer Structural Interventions device to use by suggesting applicable devices based on respective Instructions for Use.
 

Download on the Apple App Store
Download on Google Play

Learn more about Amplatzer™ Muscular VSD Occluders by visiting the Abbott Structural Heart website.

Ordering Information

AMPLATZER™ Muscular VSD Occluder
Model/Reorder NumberDevice Size/Waist Diameter (mm)Disc Diameter (mm)Waist Length (mm)
9-VSD-MUSC-004497
9-VSD-MUSC-0066147
9-VSD-MUSC-0088167
9-VSD-MUSC-01010187
9-VSD-MUSC-01212207
9-VSD-MUSC-01414227
9-VSD-MUSC-01616247
9-VSD-MUSC-01818267
 
AMPLATZER™ P.I. Muscular VSD Occluder
Model/Reorder NumberDevice Size/Waist Diameter (mm)Disc Diameter (mm)Waist Length (mm)
9-VSDMUSCPI-016162610
9-VSDMUSCPI-018182810
9-VSDMUSCPI-020203010
9-VSDMUSCPI-022223210
9-VSDMUSCPI-024243410

 

 

References

  1. Hoffman J, Kaplan S. The incidence of congential heart disease. Journal of the American College of Cardiology. 2002;39(12):1890-1900
  2. Amplatzer Muscular VSD Occluder Instructions for Use.

     

Rx Only

Important Safety Information

AMPLATZER™ MUSCULAR VSD OCCLUDER

Indication for Use

The Amplatzer™ Muscular VSD Occluder is indicated for use in patients with a complex ventricular septal defect (VSD) of significant size to warrant closure (large volume left-to-right shunt, pulmonary hypertension, and/or clinical symptoms of congestive heart failure) who are considered to be at high risk for standard transatrial or transarterial surgical closure based on anatomical conditions and/or based on overall medical condition.

High-risk anatomical factors for transatrial or transarterial surgical closure include patients: Requiring left ventriculotomy or an extensive right ventriculotomy; With a failed previous VSD closure; With multiple apical and/or anterior muscular VSDs (“Swiss cheese septum”); With posterior apical VSDs covered by trabeculae.

Contraindications

The Amplatzer™ Muscular VSD Occluder is contraindicated for the following: Patients with defects less than 4 mm distance from the semilunar (aortic and pulmonary) and atrioventricular valves (mitral and tricuspid); Patients with severely increased pulmonary vascular resistance above 7 Wood units and a right-to-left shunt and documented irreversible pulmonary vascular disease; Patients with perimembranous (close to the aortic valve) VSD; Patients with post-infarction VSD; Patients who weigh less than 5.2 kg. (Patients smaller than 5.2 kg were studied in the clinical trial, but due to poor outcome, these patients have been contraindicated for device placement. Data from these patients has not been included in the overall analysis); Patients with sepsis (local/generalized); Patients with active bacterial infections; Patients with contraindications to antiplatelet therapy or agents.

Potential Adverse Events

Potential adverse events that may occur during or after a procedure placing this device may include, but are not limited to: Air embolus; Allergic drug reaction; Allergic dye reaction; Anemia; Anesthesia reactions; Apnea; Arrhythmia; Arterial pulse loss; Atelectasis; Bacterial endocarditis; Blood loss requiring transfusion; Brachial plexus injury; Cardiac arrest; Cardiomyopathy; Chest pain; Cyanosis; Death; Device embolization; Device fracture; Fever; Headache/migraine; Heart block; Hypotension; Myocardial infarction; Perforation of the vessel or myocardium; Peripheral embolism; Stridor; Stroke; Subaortic stenosis; Thrombus formation on device; Vascular access site injury; Venous thrombosis; Vomiting.

Rx Only

Important Safety Information

AMPLATZER™ P.I. MUSCULAR VSD OCCLUDER

Indication for Use

The Amplatzer™ Post-infarct Muscular VSD Occluder is a percutaneous transcatheter occlusion device intended for closure of post-myocardial infarct muscular VSDs in patients who are not satisfactory surgical candidates.

Contraindications

The Amplatzer™ Post-infarct Muscular VSD Occluder is contraindicated for the following: Patients with perimembranous VSDs or a VSDs close to the aortic or mitral valve; Patients with congenital muscular VSDs; Patients with the presence of thrombus at the intended site of implant, or documented evidence of venous thrombus in the vessels through which access to the defect is gained; Patients with active endocarditis or other infections producing bacteremia; Patients whose vasculature, through which access to the defect is gained, is inadequate to accommodate the appropriate sheath size; Patients known to have active sepsis or any systemic infection that cannot be successfully treated prior to device placement; Any patient known to have a bleeding disorder, untreated ulcer, or any other contraindications to aspirin therapy, unless another antiplatelet agent can be administered for 6 months.

Potential Adverse Events

Potential adverse events that may occur during or after a procedure placing this device may include, but are not limited to: Air embolus; Allergic reaction; Anemia; Anesthesia reaction; Apnea; Arrhythmia; Arterial pulse loss; Atelectasis; Bacterial endocarditis; Bleeding; Brachial plexus injury; Cardiac arrest; Cardiomyopathy; Cyanosis; Chest pain; Death; Device embolization; Device fracture; Fever; Headache/migraine; Heart block; Heart failure; Hemolysis; Hypertension; Hypotension; Left ventricular aneurysm; Myocardial infarction; Perforation of vessel or myocardium; Peripheral embolism; Renal insufficiency; Respiratory arrest; Sepsis; Stridor; Stroke/TIA; Sub-aortic stenosis; Thrombocytopenia; Thrombus; Valvular regurgitation/insufficiency; Vascular access site complications; Venous thrombosis; Vomiting.

MAT-2006713 v2.0